ERCC6L promotes cell growth and invasion in human colorectal cancer

Xie,Yang; Yu,Jun; Wang,Feng; Li,Mengying; Qiu,Xiao; Liu,Yuting; Qi,Jian

doi:10.3892/ol.2019.10297

ERCC6L promotes cell growth and invasion in human colorectal cancer

Authors:
- Yang Xie
- Jun Yu
- Feng Wang
- Mengying Li
- Xiao Qiu
- Yuting Liu
- Jian Qi
View Affiliations

Affiliations: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: April 30, 2019 https://doi.org/10.3892/ol.2019.10297
Pages: 237-246
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Excision repair cross‑complementation group 6 like (ERCC6L), a recently discovered DNA helicase, has been demonstrated to be highly expressed in a variety of human cancer types. However, the precise role of ERCC6L in colorectal cancer (CRC) remains unclear. The current study aimed to investigate the potential role of ERCC6L in the development and progression of CRC. Reverse transcription‑quantitative polymerase chain reaction, western blot analysis and immunohistochemistry were used to detect the expression level of ERCC6L in 30 matched pairs of CRC and adjacent noncancerous tissues. The function of ERCC6L in cell proliferation, cycle, apoptosis, invasion and colony formation was examined in CRC cell lines. ERCC6L was revealed to be highly expressed in CRC tissues and cell lines compared with normal controls (P<0.05). The expression level of ERCC6L was significantly associated with tumor size (P<0.05), but not with other clinical features, including age, gender, differentiation and clinical stage. It was identified that reducing ERCC6L expression using small interfering RNA significantly inhibited the proliferation and colony‑forming ability of CRC cell lines. Flow cytometric analysis demonstrated that ERCC6L knockdown in CRC cells inhibited cell cycle progression and increased the number of cells in the G0/G1 phase without affecting apoptosis. Furthermore, ERCC6L knockdown markedly decreased the number of invading CRC cells compared with control cells. These results suggest that ERCC6L promotes the growth and invasion of CRC cells, and ERCC6L may be a potential new target for cancer therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Miller K and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Maurel J and Postigo A: Prognostic and predictive biomarkers in colorectal cancer. From the preclinical setting to clinical practice. Curr Cancer Drug Targets. 15:703–715. 2015. View Article : Google Scholar : PubMed/NCBI
5	Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP and Kuipers EJ: Colorectal cancer screening: A global overview of existing programmes. Gut. 64:1637–1649. 2015. View Article : Google Scholar : PubMed/NCBI
6	Dickinson BT, Kisiel J, Ahlquist DA and Grady WM: Molecular markers for colorectal cancer screening. Gut. 64:1485–1494. 2015. View Article : Google Scholar : PubMed/NCBI
7	Xu Y, Chen X and Li Y: Ercc6l, a gene of SNF2 family, may play a role in the teratogenic action of alcohol. Toxicol Lett. 157:233–239. 2005. View Article : Google Scholar : PubMed/NCBI
8	Zhao Z, Zhang G and Li W: Elevated expression of ERCC6 confers resistance to 5-fluorouracil and is associated with poor patient survival in colorectal cancer. DNA Cell Biol. 36:781–786. 2017. View Article : Google Scholar : PubMed/NCBI
9	Nielsen CF, Huttner D, Bizard AH, Hirano S, Li TN, Palmai-Pallag T, Bjerregaard VA, Liu Y, Nigg EA, Wang LH and Hickson ID: PICH promotes sister chromatid disjunction and co-operates with topoisomerase II in mitosis. Nat Commun. 6:89622015. View Article : Google Scholar : PubMed/NCBI
10	Baumann C, Körner R, Hofmann K and Nigg EA: PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell. 128:101–114. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chen XG, Li Y, Zang MX, Pei XR, Xu YJ and Gao LF: cDNA cloning and expression analysis of mouse gene encoding the protein Ercc61 which is a novel member of SNF2 family. Prog Biochem Biophys. 31:443–448. 2004.
12	Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, Prechtl S, Schulze V, Siemeister G, Wortmann L, et al: Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 18:4024–4036. 2007. View Article : Google Scholar : PubMed/NCBI
13	Pu SY, Yu Q, Wu H, Jiang JJ, Chen XQ, He YH and Kong QP: ERCC6L, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers. Oncotarget. 8:42116–42124. 2017. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
16	Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal tumor development. N Engl J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
17	Jagadish N, Parashar D, Gupta N, Agarwal S, Purohit S, Kumar V, Sharma A, Fatima R, Topno AP, Shaha C and Suri A: A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer. J Exp Clin Cancer Res. 34:1422015. View Article : Google Scholar : PubMed/NCBI
18	Mhaidat NM, Alzoubi KH and Abushbak A: X-box binding protein 1 (XBP-1) enhances colorectal cancer cell invasion. J Chemother. 27:167–173. 2015. View Article : Google Scholar : PubMed/NCBI
19	Zhou FF, Xie W, Chen SQ, Wang XK, Liu Q, Pan XK, Su F and Feng MH: SLC38A1 promotes proliferation and migration of human colorectal cancer cells. J Huazhong Univ Sci Technolog Med Sci. 37:30–36. 2017. View Article : Google Scholar : PubMed/NCBI
20	Gil-Raga M, Jantus-Lewintre E, Gallach S, Giner-Bosch V, Frangi-Caregnato A, Safont-Aguilera MJ, Garde-Noguera J, Zorraquino-Pina E, García-Martínez M and Camps-Herrero C: Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clin Transl Oncol. 20:1422–1429. 2018. View Article : Google Scholar : PubMed/NCBI
21	Liu J, Deng N, Xu Q, Sun L, Tu H, Wang Z, Xing C and Yuan Y: Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer. Oncotarget. 7:48130–48142. 2016.PubMed/NCBI
22	Xu Q, Liu JW, He CY, Sun LP, Gong YH, Jing JJ, Xing CZ and Yuan Y: The interaction effects of pri-let-7a-1 rs10739971 with PGC and ERCC6 gene polymorphisms in gastric cancer and atrophic gastritis. PLoS One. 9:e892032014. View Article : Google Scholar : PubMed/NCBI
23	Taghdiri M, Dastsooz H, Fardaei M, Mohammadi S, Farazi Fard MA and Faghihi MA: A novel mutation in ERCC8 gene causing cockayne syndrome. Front Pediatr. 5:1692017. View Article : Google Scholar : PubMed/NCBI
24	Xie H, Li X, Peng J, Chen Q, Gao Z, Song X, Li W, Xiao J, Li C, Zhang T, et al: A complex intragenic rearrangement of ERCC8 in Chinese siblings with Cockayne syndrome. Sci Rep. 7:442712017. View Article : Google Scholar : PubMed/NCBI
25	He C, Sun M, Wang G, Yang Y, Yao L and Wu Y: Two novel mutations in ERCC6 cause Cockayne syndrome B in a Chinese family. Mol Med Rep. 15:3957–3962. 2017. View Article : Google Scholar : PubMed/NCBI
26	Truta A, Popon TA, Saraci G, Ghervan L and Pop IV: Novel non invasive diagnostic strategies in bladder cancer. Clujul Med. 89:187–192. 2016.PubMed/NCBI
27	Kurasawa Y and Yu-Lee LY: PICH and cotargeted Plk1 coordinately maintain prometaphase chromosome arm architecture. Mol Biol Cell. 21:1188–1199. 2010. View Article : Google Scholar : PubMed/NCBI
28	Leng M, Besusso D, Jung SY, Wang Y and Qin J: Targeting Plk1 to chromosome arms and regulating chromosome compaction by the PICH ATPase. Cell Cycle. 7:1480–1489. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ke Y, Huh JW, Warrington R, Li B, Wu N, Leng M, Zhang J, Ball HL, Li B and Yu H: PICH and BLM limit histone association with anaphase centromeric DNA threads and promote their resolution. EMBO J. 30:3309–3321. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kaulich M, Cubizolles F and Nigg EA: On the regulation, function, and localization of the DNA-dependent ATPase PICH. Chromosoma. 121:395–408. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ma X, Wang L, Huang, Li Y, Yang D, Li T, Li F, Sun L, Wei H, He K, et al: Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nat Commun. 8:15062017. View Article : Google Scholar : PubMed/NCBI
32	Helmke C, Becker S and Strebhardt K: The role of Plk3 in oncogenesis. Oncogene. 35:135–147. 2016. View Article : Google Scholar : PubMed/NCBI
33	Yen TJ: Polo delivers a PICH to the kinetochore. Cell. 128:20–21. 2007. View Article : Google Scholar : PubMed/NCBI
34	Baines AT, Xu D and Der CJ: Inhibition of Ras for cancer treatment: The search continues. Future Med Chem. 3:1787–1808. 2011. View Article : Google Scholar : PubMed/NCBI
35	Sclafani F, Gullo G, Sheahan K and Crown J: BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 87:55–68. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, et al: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep. 5:186782015. View Article : Google Scholar : PubMed/NCBI
37	McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, et al: Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 25:621–637. 2014. View Article : Google Scholar : PubMed/NCBI
38	Nguyen-Ngoc T, Bouchaab H, Adjei AA and Peters S: BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol. 10:1396–1403. 2015. View Article : Google Scholar : PubMed/NCBI